, a bio/informatics shared resource is still "open for business" - Visit the CDS website


Acute lymphoblastic leukemia.

Alvarnas JC, Brown PA, Aoun P, Ballen KK, Bellam N, Blum W, Boyer MW, Carraway HE, Coccia PF, Coutre SE, Cultrera J, Damon LE, DeAngelo DJ, Douer D, Frangoul H, Frankfurt O, Goorha S, Millenson MM, O'Brien S, Petersdorf SH, Rao AV, Terezakis S, Uy G, Wetzler M, Zelenetz AD, Naganuma M, Gregory KM, National Comprehensive Cancer Network
J Natl Compr Canc Netw. 2012 10 (7): 858-914

PMID: 22773801 · DOI:10.6004/jnccn.2012.0089

The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.

MeSH Terms (6)

Humans Neoplasm, Residual Philadelphia Chromosome Precursor Cell Lymphoblastic Leukemia-Lymphoma Prognosis Risk Factors

Connections (1)

This publication is referenced by other Labnodes entities:

Links